Chairs: R. Herrmann, Basel / N. Saijo, Tokyo

Biomarkers profile and clinical factors in selecting patients
A.B. Sandler, Portland
Presentation PDF

Imaging in targeted therapy
C. Fink, Mannheim
Presentation PDF

Management of toxicity of anti-angiogenic/anti-EGFR agents
J. Heymach, Houston
Presentation PDF

Integrin inhibitors
S. Peters, Lausanne
Presentation PDF

Vascular disrupting agents
J.Y. Doulliard, Nantes
Presentation PDF

Anti-angiogenic TKI’s
U. Gatzemeier, Großhansdorf
Presentation PDF

Molecular biology
E. Voest, Utrecht

Chairs: W. Eberhardt, Essen / T. Le Chevalier, Paris

Heat shock protein targeting agents
K. O’Byrne, Dublin
Presentation PDF

Histone deacetylase inhibitors
S. Ramalingam, Atlanta
Presentation PDF

PARP1-inhibitors
J.-C. Soria, Paris
Presentation PDF

Dendritic cell recruitors and activators
A. Y. Chang, Singapore
Presentation PDF

Vaccine therapy
J. Vansteenkiste, Leuven
Presentation PDF

Pro-apoptotic agents
F. R. Khuri, Atlanta
Presentation PDF

Targeted therapy: how to clinically develop new agents and treatment strategies based on pre-clinical information
P. Bunn, Denver
Presentation PDF

Chairs: N.Thatcher, Manchester / K. Syrigos, Athens

Molecular biology of the EGFR-pathway
A. F. Gazdar, Dallas
Presentation PDF

Clinical and molecular predictors of EGFR-TKI sensitivity
F. A. Shepherd, Toronto
Presentation PDF

Mechanism of drug resistance and how to overcome first generation EGFR- TKI failure
P. A. Jänne, Boston
Presentation PDF

EGFR-TKI first-line therapy: diagnostic assessment and drug selection
T. Mok, Hong Kong
Presentation PDF

EGFR-assessment in prospective clinical trials
R. Dziadziusko, Gdansk
Presentation PDF

Treatment duration and sequencing of EGFR-TKI inhibitors
F. Cappuzzo, Livorno
Presentation PDF

EGFR-targeting antibodies: clinical and molecular sensitivity predictors
R. Pirker, Vienna
Presentation PDF

EGFR-targeting antibodies in combination with radiotherapy
F. Mornex, Lyon
Presentation PDF

Chairs: F. Blackhall, Manchester / C. Manegold, Mannheim

Relevance of TS testing: British experience
K. Kerr, Aberdeen
Presentation PDF

Pharmacogenomic guided treatment strategies for early NSCLC
G. V. Scagliotti, Torino
Presentation PDF

Pemetrexed (Alimta therapy): duration and frequency
C. Belani, Hersey
Presentation PDF

Chairs: N. van Zandwijk, Sydney / J. Niklinski, Bialystok

Molecular basis
H. Allgayer, Mannheim
Presentation PDF

Proteomics and outcome prediction
D. P. Carbone, Nashville

Rationale for Genomic Guided Molecular Therapy in Lung Cancer
A. Potti, Durham / N. Ready, Durham
Presentation PDF

MicroRNA signatures and outcome prediction
P.-C. Yang, Taiwan
Presentation PDF

TS-expression and sensitivity to anti-folates
G. V. Scagliotti, Torino
Presentation PDF

ERCC1, RRM1, and BRCA1-gene expression and outcome prediction
G. Bepler, Detroit
Presentation PDF

Tumor histology and clinical outcome
C. Manegold, Mannheim
Presentation PDF

Chairs: P. Postmus, Amsterdam / J. S. Lee, Seoul

ACT, MAPK, MEK-inhibitors
A. Adjei, Buffalo
Presentation PDF

ALK, MET-inhibitors
R. Stahel, Zürich
Presentation PDF

SRC-targeting agents
O. Gautschi, Bern
Presentation PDF

m-Tor-inhibitors
L. Crinò, Perugia
Presentation PDF

Insulin growth factor receptor targeting agents
L. Paz-Ares, Sevilla
Presentation PDF

(supported by an Eli-Lilly unrestricted educational grant)

Chairs: L.R. Pilz, Heidelberg / K. Park, Seoul

WHO perspectives in reducing lung cancer mortality
A. Ullrich, Geneva
Presentation PDF

Tobacco control policy in Poland
J. Jassem, Gdansk
Presentation PDF

Smoking cessation in women
C. M. Dresler, Littler Rock
Presentation PDF

Female gender as a prognostic and predictive factor
S. Novello, Torino
Presentation PDF

New targets for chemoprevention
Y. E. Miller, Denver
Presentation PDF

Chemoprevention of high risk patient populations
N. van Zandwijk, Sydney
Presentation PDF

Chairs: D. H. Grunenwald, Paris / C. Zhou, Shanghai

Implications of the new TNM system for the surgical management of early stage lung cancer
P. Goldstraw, London
Presentation PDF

Implications of the new TNM system for modern imaging
S. Schönberg, Mannheim / C. Fink, Mannheim
Presentation PDF

Minimally invasive non-surgical methods for staging lung cancer
F. Herth, Heidelberg
Presentation PDF

Adjuvant chemotherapy
B. Besse, Paris
Presentation PDF

Induction chemotherapy
P. van Schil, Antwerp
Presentation PDF

Advanced NSCLC: maintenance therapy
C. Belani, Hersey
Presentation PDF

Chairs: P. Hohenberger, Mannheim / E. Smit, Amsterdam

Stereotactic radiation therapy for stage I NSCLC
F. Wenz, Mannheim
Presentation PDF

Chemo-radiation
D. de Ruysscher, Maastricht
Presentation PDF

Is thymic carcinoma a specific entity?
A. Marx, Mannheim / P. Ströbel, Mannheim
Presentation PDF

Malignant pleural mesothelioma: extension of surgery
W. Weder, Zurich
Presentation PDF

Malignant pleural mesothelioma: new drug development
D. Fennell, Belfast
Presentation PDF

SCLC: Combined modality therapy in limited stage disease
A. Ardizzoni, Parma
Presentation PDF